Anxiety in the elderly

Close metadata

Recommended articles:

Trait and state anxiety, symptoms of insomnia and their influence on daytime functioning in adolescent girls. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(5-2):66-71

Recognan (citicoline) in the correction of asthenic and anxiety-depressive disorders. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(6):43-47

Fluvoxamine in the treatment of anxiety-depressive spectrum disorders. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(6):101-109

Anxiety disorders as comorbid conditions in neuropsychiatric diseases in children. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(7):56-64

The association of single-nucleotide polymorphism rs6265 of the brain-derived neurotrophic factor gene with clinical features in Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(7):82-88

Efficacy and safety of Aviandr in the treatment of anxiety in patients with adjustment disorders after COVID-19. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(7):131-138

Determining the risk of maladaptation using an electroencephalogram to prevent mental strain. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(8):97-102

Factors affecting the quality of life of patients with neurological manifestations of post-COVID syndrome. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(9):44-50

The syndrome of psycho-sensory-anatomical-functional auto-desadaptation in patients with malignant tumors of the maxillofacial region. Stomatology. 2024;(4):20-27

Impact of various rehabilitation programs on anxiety and depression after surgery of early-stage cervical cancer. Problems of Balneology, Physiotherapy and Exercise Therapy. 2024;(5):40-44

Anxiety occurs in about one third of people over 65 years of age. However, its identification in this age has significant difficulties. The clinical manifestations, pathogenetic mechanisms, approaches to the diagnosis and treatment of various types of anxiety are described in the article. Particular attention is paid to the comorbidity of anxiety disorders in elderly patients. A comprehensive approach to the treatment of elderly patients with anxiety includes psychotherapeutic and pharmacotherapeutic approaches. Special attention should be paid to the efficacy and safety of the drugs, which is especially important in this category of patients.

Keywords:

anxiety

elderly patients

buspirone

tofisopam

Authors:

Levin O.S.

Rossiĭskaia meditsinskaia akademiia poslediplomnogo obrazovaniia

SPIN RSCI: 5342-1373
Scopus AuthorID: 57147160800
ORCID: 0000-0003-3872-5923

Chimagomedova A.Sh.

Russian Medical Academy of Postgraduate Education, Moscow, Russia

Arefieva A.P.

Russian Medical Academy for Continuing Professional Education, Moscow, Russia

List of references:

Javed A, Fountoulakis K. Advances in Psychiatry. Springer. 2019;33-59. https://doi.org/10.1007/978-3-319-70554-5
Kessler RC, Aguilar-Gaxiola S, Alonso J, Chatterji S, Lee S, Ormel J, Ustün TB, Wang PS. The global burden of mental disorders: an update from the WHO world mental health (WMH) surveys. Epidemiol Psichiatr Soc. 2009;18(1):23-33. https://doi.org/10.1017/S1121189X00001421
Baxter AJ, Patton G, Scott KM, Degenhardt L, Whiteford HA. Global epidemiology of mental disorders: what are we missing? PLoS One. 2013;8(6): e65514. https://doi.org/10.1371/journal.pone.0065514
Steel Z, Marnane C, Iranpour C, Chey T, Jackson JW, Patel V, Silove D. The global prevalence of common mental disorders: a systematic review and meta-analysis 1980—2013. Int J Epidemiol. 2014;43(2):476-493. https://doi.org/10.1093/ije/dyu038
Baxter AJ, Scott KM, Vos T, Whiteford HA. Global prevalence of anxiety disorders: a systematic review and meta-regression. Psychol Med. 2013;43(5):897-910.
de Jonge P, Roest AM, Lim CC, Florescu SE, Bromet EJ, Stein DJ, Harris M, Nakov V, Caldas-de-Almeida JM, Levinson D, Al-Hamzawi AO, Haro JM, Viana MC, Borges G, O’Neill S, de Girolamo G, Demyttenaere K, Gureje O, Iwata N, Lee S, Hu C, Karam A, Moskalewicz J, Kovess-Masfety V, Navarro-Mateu F, Browne MO, Piazza M, Posada-Villa J, Torres Y, Ten Have ML, Kessler RC, Scott KM. Cross-national epidemiology of panic disorder and panic attacks in the world mental health surveys. Depress Anxiety. 2016;33(12):1155-1177. https://doi.org/10.1002/da.22572
Slade T, McEvoy PM, Chapman C, Grove R, Teesson M. Onset and temporal sequencing of lifetime anxiety, mood and substance use disorders in the general population. Epidemiol Psychiatr Sci. 2015;24(1):45-53. https://doi.org/10.1017/S2045796013000577
Diagnostic and statistical manual of mental disorders, 5th ed. American Psychiatric Association; 2013. https://doi.org/10.4103/0019-5545.117131
Stein DJ. Advances in understanding the anxiety disorders: the cognitive-affective neuroscience of «false alarms». Ann Clin Psychiatry. 2006;18(3):10. https://doi.org/10.1080/10401230600801192
Fox AS, Kalin NH. A translational neuroscience approach to understanding the development of social anxiety disorder and its pathophysiology. Am J Psychiatry. 2014;171(11):1162-1173. https://doi.org/10.1176/appi.ajp.2014.14040449
Hofmeijer-Sevink MK, Batelaan NM, van Megen HJ, Penninx BW, Cath DC, van den Hout MA, van Balkom AJ. Clinical relevance of comorbidity in anxiety disorders: a report from the Netherlands Study of Depression and Anxiety (NESDA). J Affect Disord. 2012;137(1-3):106-112. https://doi.org/10.1016/j.jad.2011.12.008
Williams LM, Goldstein-Piekarski AN, Chowdhry N, Grisanzio KA, Haug NA, Samara Z, Etkin A, O’Hara R, Schatzberg AF, Suppes T, Yesavage J. Developing a clinical translational neuroscience taxonomy for anxiety and mood disorder: protocol for the baseline-follow up Research domain criteria Anxiety and Depression («RAD») project. BMC Psychiatry. 2016; 16:68. https://doi.org/10.1186/s12888-016-0771-3
Research Domain Criteria (RDoC): National Institute of Mental Health; 2017. Available from: https://www.nimh.nih.gov/research-priorities/rdoc/index.shtml
Cryan JF, Sweeney FF. The age of anxiety: role of animal models of anxiolytic action in drug discovery. Br J Pharmacol. 2011;164(4):1129-1161. https://doi.org/10.1111/j.1476-5381.2011.01362.x
Martin EI, Ressler KJ, Binder E, Nemeroff CB. The neurobiology of anxiety disorders: brain imaging, genetics, and Psychoneuroendocrinology. Psychiatr Clin North Am. 2009;32(3):549-575. https://doi.org/10.1016/j.psc.2009.05.004
Bishop SJ. Neurocognitive mechanisms of anxiety: an integrative account. Trends Cogn Sci. 2007;11(7):307-316. https://doi.org/10.1016/j.tics.2007.05.008
Brühl AB, Delsignore A, Komossa K, Weidt S. Neuroimaging in social anxiety disorder — a meta-analytic review resulting in a new neurofunctional model. Neurosci Biobehav Rev. 2014;47:260-280. https://doi.org/10.1016/j.neubiorev.2014.08.003
Mathew SJ, Price RB, Charney DS. Recent advances in the neurobiology of anxiety disorders: implications for novel therapeutics. Am J Med Genet C Semin Med Genet. 2008;148C(2):89-98. https://doi.org/10.1002/ajmg.c.30172
Morrison FG, Ressler KJ. From the neurobiology of extinction to improved clinical treatments. Depress Anxiety. 2014;31(4):279-290. https://doi.org/10.1002/da.22214
Milad MR, Rosenbaum BL, Simon NM. Neuroscience of fear extinction: implications for assessment and treatment of fear-based and anxiety related disorders. Behav Res Ther. 2014;62:17-23. https://doi.org/10.1016/j.brat.2014.08.006
Olivier JD, Vinkers CH, Olivier B. The role of the serotonergic and GABA system in translational approaches in drug discovery for anxiety disorders. Front Pharmacol. 2013;4:74. https://doi.org/10.3389/fphar.2013.00074
Kindt M. A behavioural neuroscience perspective on the aetiology and treatment of anxiety disorders. Behav Res Ther. 2014;62:24-36. https://doi.org/10.1016/j.brat.2014.08.012
Harvey BH, Shahid M. Metabotropic and ionotropic glutamate receptors as neurobiological targets in anxiety and stress-related disorders: focus on pharmacology and preclinical translational models. Pharmacol Biochem Behav. 2012;100(4):775-800. https://doi.org/10.1016/j.pbb.2011.06.014
Kormos V, Gaszner B. Role of neuropeptides in anxiety, stress, and depression: from animals to humans. Neuropeptides. 2013;47(6):401-419. https://doi.org/10.1016/j.npep.2013.10.014
Colasanti A, Rabiner EA, Lingford-Hughes A, Nutt DJ. Opioids and anxiety. J Psychopharmacol. 2011;25(11):1415-1433. https://doi.org/10.1177/0269881110367726
Katzman MA, Bleau P, Blier P, Chokka P, Kjernisted K, Van Ameringen M. Canadian Anxiety Guidelines Initiative Group on behalf of the Anxiety Disorders Association of Canada/Association Canadienne des troubles anxieux and McGill University, Antony MM, Bouchard S, Brunet A, Flament M, Grigoriadis S, Mendlowitz S, O’Connor K, Rabheru K, Richter PM, Robichaud M, Walker JR. Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessivecompulsive disorders. BMC Psychiatry. 2014;14(suppl 1):1. https://doi.org/10.1186/1471-244X-14-S1-S1
Taylor D, Paton C, Kapur S. The Maudsley prescribing guidelines in psychiatry. 11th ed. New Jersey: Wiley-Blackwell; 2012.
Excellence NIfHaC. Generalised anxiety disorder and panic disorder in adults: management. NICE guideline (CG113) [Internet]. 2011.
Bandelow B, Reitt M, Röver C, Michaelis S, Görlich Y, Wedekind D. Efficacy of treatments for anxiety disorders: a meta-analysis. Int Clin Psychopharmacol. 2015;30(4):183-192. https://doi.org/10.1097/YIC.0000000000000078
Ougrin D. Efficacy of exposure versus cognitive therapy in anxiety disorders: systematic review and meta-analysis. BMC Psychiatry. 2011;11(1):200. https://doi.org/10.1186/1471-244X-11-200
Linden M, Schermuly-Haupt M-L. Definition, assessment and rate of psychotherapy side effects. World Psychiatry. 2014;13(3):306-309. https://doi.org/10.1002/wps.20153
Berk M, Parker G. The elephant on the couch: side-effects of psychotherapy. Aust N Z J Psychiatry. 2009;43(9):787-794. https://doi.org/10.1080/00048670903107559
Campbell-Sills L, Roy-Byrne PP, Craske MG, Bystritsky A, Sullivan G, Stein MB. Improving outcomes for patients with medication-resistant anxiety: effects of collaborative care with cognitive behavioral therapy. Depress Anxiety. 2016;33(12):1099-1106. https://doi.org/10.1002/da.22574
Hofmann SG, Mundy EA, Curtiss J. Neuroenhancement of exposure therapy in anxiety disorders. AIMS Neurosci. 2015;2(3):123-138. https://doi.org/10.3934/Neuroscience.2015.3.123
Kawalec P, Cierniak A, Pilc A, Nowak G. Pregabalin for the treatment of social anxiety disorder. Expert Opin Investig Drugs. 2015;24(4):585-594. https://doi.org/10.1517/13543784.2014.979283
Feltner DE, Liu-Dumaw M, Schweizer E, Bielski R. Efficacy of pregabalin in generalized social anxiety disorder: results of a double-blind, placebo-controlled, fixed-dose study. Int Clin Psychopharmacol. 2011;26(4):213-220. https://doi.org/10.1097/YIC.0b013e32834519bd
Mayo-Wilson E, Dias S, Mavranezouli I, Kew K, Clark DM, Ades AE, Pilling S. Psychological and pharmacological interventions for social anxiety disorder in adults: a systematic review and network meta-analysis. Lancet Psychiatry. 2014;1(5):368-376. https://doi.org/10.1016/S2215-0366(14)70329-3
Stein MB, Sareen J. CLINICAL PRACTICE. Generalized Anxiety Disorder. N Engl J Med. 2015;373(21):2059-2068. https://doi.org/10.1056/NEJMcp1502514
Baldwin DS, Anderson IM, Nutt DJ, Allgulander C, Bandelow B, den Boer JA, Christmas DM, Davies S, Fineberg N, Lidbetter N, Malizia A, McCrone P, Nabarro D, O’Neill C, Scott J, van der Wee N, Wittchen HU. Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: a revision of the 2005 guidelines from the British Association for Psychopharmacology. J Psychopharmacol. 2014;28(5):403-439. https://doi.org/10.1177/0269881114525674

Close metadata